Aktuellt
SENASTE
Alnylam Pharmaceuticals (BB Biotech has 4.3% stake) reported positive Ph3 results for Vutrisiran in ATTR cardiomyopathy, a potentially fatal heart disease. Vutrisiran enhanced cardiovascular outcomes, including survival, function, and quality of life, for all patients with the disease. Alnylam share is up 43%, boosting the NAV value of BB Biotech's portfolio. Investors can currently buy into BB Biotech at a 7% discount to the net asset value of the fund's underlying portfolio.
LÄS MER
